Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New FDA external relations head

This article was originally published in The Tan Sheet

Executive Summary

Sheila Dearybury Walcoff is named FDA associate commissioner for exteral relations, the agency announces Sept 7. Walcoff will advise Acting Commissioner Lester Crawford, PhD, on executive-level policy and program direction for FDA's interactions and liason activities. Walcoff most recently served as a senior associate at the law firm Mayer, Brown, Rowe & Maw (Washington, D.C.). She replaces Peter Pitts, who left the position in June to pursue an opportunity in the private sector (1"The Tan Sheet" June 7, 2004, p. 8)...

You may also be interested in...



FDA External Relations Head Pitts To Leave Agency; CFSAN’s Bond Moves Up

FDA Associate Commissioner for External Relations Peter Pitts is leaving after 14 months at the agency to join the public relations firm Manning, Selvage & Lee

EU Critical Medicines List To Be Ready ‘Within Days’

Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.

Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration

With Biocon Biologics having previously integrated its acquisition of Viatris’s biosimilars business in emerging markets and North America, the firm has now completed integration in Europe. In an exclusive interview, CEO Shreehas Tambe tells Generics Bulletin what this means for the company and reveals the opportunities it perceives ahead.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel